Palisade Bio, Inc. (PALI)
| Market Cap | 5.03M |
| Revenue (ttm) | 250,000 |
| Net Income (ttm) | -13.44M |
| Shares Out | 9.20M |
| EPS (ttm) | -3.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307,013 |
| Open | 0.580 |
| Previous Close | 0.580 |
| Day's Range | 0.530 - 0.586 |
| 52-Week Range | 0.530 - 8.540 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 33.00 (+5,939.53%) |
| Earnings Date | Nov 13, 2023 |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price forecast is $33.0, which is an increase of 5,939.53% from the latest price.
News
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announ...
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutica...
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announ...
Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies
Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade said th...
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024
Palisade Bio Reports Second Quarter 2023 Financial Results
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Topline data expect ed in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chron...
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Live webcast fireside chat on Thursday, June 22 nd at 11:30 AM ET
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal...
Palisade Bio's LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
Company approaching Phase 2 t opline dat a readout for prevention of post-surgical abdominal adhesions
Palisade Bio Reports First Quarter 2023 Financial Results
Company has sufficient cash expected to fund operations through 2024
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing effica cy
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complica...
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
Enrollment t riggers m ilestone p ayment
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Phase 2 t opline dat a readout for prevention of post-surgical abdominal adhesions o n track for Q2 2023
Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent
Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestina...
Palisade Bio Promotes Robert McRae to Chief Operating Officer
Mr. McRae is an i ndustry veteran with a proven track record of operational , clinical , and strategic business development execution
Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million
Proceeds expected to extend cash runway to fund operations into the second half of 2024
Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17 th at 3:00 PM ET
Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complicati...
Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complicati...
Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
Topline data readout from study expected i n first half of 2023
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
Proceeds extend cash runway to fund operations into early 2024
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complicati...